Resources

Selected
  • COVID-19
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)
1513 results found
2023 ∙ Camargo-Coronel, A. Quiñones-Moya, H. Hernández-Zavala, M. R. Hernández-Vázquez, J. R. Vázquez-Zaragoza, MÁ
Idiopathic inflammatory myopathies linked to vaccination against SARS-CoV-2: a systematic review
Adults Older adults COVID-19 Safety
Rating:
Critically low
2023 ∙ Shi, H. Sun, J. Zeng, Y. Wang, X. Liu, S. Zhang, L. Shao, E.
Immune escape of SARS-CoV-2 variants to therapeutic monoclonal antibodies: a system review and meta-analysis
Adults Older adults COVID-19 Efficacy/effectiveness Administration
Rating:
Critically low
2023 ∙ Ho, T. C. Shen, D. H. Chang, C. C. Chan, H. P. Chuang, K. P. Yuan, C. H. Chen, C. N. Yang, M. H. Tyan, Y. C.
Immune Response Related to Lymphadenopathy Post COVID-19 Vaccination
All age groups COVID-19 Efficacy/effectiveness
Rating:
Critically low
2023 ∙ Cheng, M. Q. Li, R. Weng, Z. Y. Song, G.
Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis
All age groups COVID-19 Efficacy/effectiveness
Rating:
Critically low
2023 ∙ Karofi, D. H. Lawal, N. Bello, M. B. Imam, M. U.
Immunogenicity and Protective Efficacy of Nucleic Acid-Based Vaccines Against COVID-19: A Systematic Review
All age groups COVID-19 Efficacy/effectiveness
Rating:
Critically low
2023 ∙ Katoto, P. D. Kakubu, M. A. Tamuzi, J. L. Brand, A. S. Ayuk, A. Byamungu, L. N. Wiysonge, C. S. Gray, G.
Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses
Adolescents Adults COVID-19 Efficacy/effectiveness Safety
Rating:
Low
2023 ∙ Li, P. Wang, W. Tao, Y. Tan, X. Li, Y. Mao, Y. Gao, L. Feng, L. Zhan, S. Sun, F.
Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis
Adults COVID-19 Administration Efficacy/effectiveness Safety
Rating:
Critically low
2023 ∙ Cheng, M. Q. Li, R. Luo, X. Chen, J. Y. Bai, Z. P. Zhao, P. Weng, Z. Y. Song, G.
Immunogenicity and safety of adjuvant-associated COVID-19 vaccines: A systematic review and meta-analysis of randomized controlled trials
All age groups COVID-19 Efficacy/effectiveness Safety
Rating:
Critically low
2023 ∙ Zhao, T. Yang, Z. Wu, Y. Yang, J.
Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis
All age groups COVID-19 Efficacy/effectiveness Safety
Rating:
Low
2023 ∙ Vasconcelos, Z. S. Salem, H. A. Veiga, S. P. Lima, F. E. B. Gonçalves, Crds Santos, E. C. D. Brandão, A. R. J. Couceiro, K. N. Guerra, J. A. O. Guerra, Mdgvb
Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis
Adults Older adults COVID-19 Efficacy/effectiveness
Rating:
Critically low
Loading...